
The Competition and Markets Authority (CMA) has ordered technology platform FNZ to abandon a long running attempt to purchase rival GBST.
A £220 million (US$288.7 million) tie-up had been launched in mid 2019 but was paused after the CMA began to probe the impact of a merger between two of the UK’s three big IFA tech providers. The business would have accounted for nearly half the UK market.
The regulator judged that the merger could lead to a reduction in quality of service and higher prices in the supply of technology to UK retail investment platforms.
Martin Coleman, chair of the inquiry group carrying out the investigation, said, “FNZ and GBST compete with each other closely and face few other suppliers of similar standing. The merger has substantially reduced competition in this sector.”
This matters to the millions of UK consumers who hold pensions or other investments. This is because competition plays a key role in driving price and quality. Without healthy competition, costs could go up and service quality could get worse.
The CMA considered a number of other options, but found that requiring FNZ to abandon the deal was the “only solution that will properly address the loss of competition resulting from the merger.” The announcement confirms a preliminary ruling in August.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas